
News
Keep up to date with our recent breakthroughs and partnerships as we develop novel life changing therapeutics for a range of inflammatory and fibrotic diseases.
Latest updates

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications
Oslo, Norway, 23 October 2024: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory...
Read more
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board
Executive appointments will drive growth strategy and progression of clinical pipeline Oslo, Norway and Boston, MA, 9 October 2024: Calluna...
Read more
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs
Read more
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.
Read moreDownload Our Investor Presentation
Download presentation
"*" indicates required fields
